<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385136</url>
  </required_header>
  <id_info>
    <org_study_id>zjzlyy 2015-1-5</org_study_id>
    <nct_id>NCT02385136</nct_id>
  </id_info>
  <brief_title>Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases</brief_title>
  <official_title>Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hangzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile and efficacy of whole brain
      radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases
      (BM).Patients with BM were randomly assigned to 30 Gy of WBRT with or without concomitant TMZ
      (75 mg/m2/d) plus two cycles of TMZ (200 mg/m2/d for 5 days).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>1 month post procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to central nervous system progress which was confirmed by MRI</measure>
    <time_frame>1 to 24 months post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Quality of Life</measure>
    <time_frame>0 to 24 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 to 24 months post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by CTCAE V4.0</measure>
    <time_frame>0 to 24 months post procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>WBRT plus TMZ arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WBRT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>whole brain radiotherapy (WBRT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>WBRT plus TMZ arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically diagnosed as NSCLC, stage IVb [ (American Joint of Cancer
             Committee(AJCC), 2002) ], Brain metastasis

          -  no history of hypertension or diabetes.

        Exclusion Criteria:

          -  the brain tumor diameter &gt;5cm; RPA class =3; pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>chenjianxiang</investigator_full_name>
    <investigator_title>Dr Chen</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Radiotherpy</keyword>
  <keyword>Temozolomide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

